藥品參考
Amivantamab
Amivantamab is a medicine in the class oncology. It is used for non-small cell lung cancer.
- 藥物類別: Oncology
- 用途: non-small cell lung cancer
最後更新 來源: US FDA label
僅供醫療專業人員參考。本頁為簡要摘要，並非醫療建議，亦不能取代官方仿單或臨床判斷。開立處方或調劑前請務必核實。
本頁的臨床內容僅提供英文版。
重點資訊
- 藥物類別
- Oncology
- ATC 代碼
- L01FX18
- 常見劑型
- 注射劑
- 常見規格
- 350 mg
- 已知交互作用
- 1 (中度: 1)
- 商品名
- 2
- 國家與市場
- 2
用途
作用方式
Bispecific antibody that binds the extracellular domains of EGFR and MET, disrupting EGFR and MET signaling by blocking ligand binding or causing receptor degradation.
成人常用劑量（仿單摘要）
NSCLC, with lazertinib or as single agent, under 80 kg: 1,050 mg IV weekly for Weeks 1-5 (split infusion on Day 1 and Day 2 of Week 1), no dose Week 6, then every 2 weeks from Week 7; until progression or unacceptable toxicity.
懷孕與哺乳
- 懷孕
- Unsafe Can cause fetal harm based on its mechanism (EGFR and MET blockade); no human data. Antibodies cross the placenta. Confirm pregnancy status before starting; use effective contraception during treatment and for 3 months after the last dose.
- 哺乳
- Unsafe No data on milk levels or infant effects. Advise not to breastfeed during treatment and for 3 months after the last dose.
已通報的副作用
- Rash
- Infusion-related reaction
- Nail toxicity
- Musculoskeletal pain
- Stomatitis
- Fatigue
哪些人需要特別留意
- Infusion-related reactions including anaphylaxis: premedicate, interrupt infusion at first sign, reduce rate or discontinue; permanently discontinue for anaphylaxis.
- Severe and fatal ILD/pneumonitis: withhold if suspected, permanently discontinue if confirmed.
- Serious and fatal VTE with lazertinib: give prophylactic anticoagulation for first four months; vitamin K antagonists not recommended.
請告知藥師或醫師您是否懷孕或哺乳、是否患有腎臟或肝臟疾病、是否有過敏，以及您正在使用的所有其他藥物或保健品。
重要交互作用 (1)
- Amivantamab + Lazertinib Moderate
同類別的其他藥品
常見問題
What is Amivantamab used for?
Amivantamab is a medicine in the class oncology. It is used for Non-small cell lung cancer.
What side effects have been reported with Amivantamab?
Rash, Infusion-related reaction, Nail toxicity, Musculoskeletal pain, Stomatitis, Fatigue.
Can Amivantamab be taken in pregnancy or while breastfeeding?
Pregnancy: Unsafe. Can cause fetal harm based on its mechanism (EGFR and MET blockade); no human data. Antibodies cross the placenta. Confirm pregnancy status before starting; use effective contraception during treatment and for 3 months after the last dose. Breastfeeding: Unsafe. No data on milk levels or infant effects. Advise not to breastfeed during treatment and for 3 months after the last dose.
What does Amivantamab interact with?
MediHelp lists 1 known interactions for Amivantamab. Moderate: 1. The most serious include Lazertinib.
在 MediHelp App 中取得完整藥品專論、劑量資訊與交互作用檢查
在 MediHelp App 中開啟完整參考資料、檢查多種藥物間的交互作用，並使用劑量工具。
